Over roughly the last week (≈8–15 June 2026), the most concrete vaccine developments have been: (1) further consolidation of adult pneumococcal and RSV strategies in Australia, (2) new Canadian COVID-19 guidance for fall 2026, and (3) WHO and Gavi moves on prequalification procedures and Phase 6 strategy; no major new phase 3 readouts or product approvals from the large vaccine manufacturers were identified in this window. Asia (incl. Southeast Asia, China, India) Over the past week, no new national immunisation schedules or NITAG policy statements with immediate programmatic impact were identified from major Asian markets (SE Asia, China, India) in English language sources. Australia and New Zealand Adult pneumococcal schedule change (effective 1 July, announced and operationalized this week) From 1 July 2026, Australia will introduce the 21-valent pneumococcal conjugate vaccine Capvaxive (PCV21) onto the National Immunization Program (NIP) adult schedule, replacing Prevenar 13 and Pneumovax 23 for funded adult use. Capvaxive will be funded...
🔒 Premium Content - For Free
Unlock this content by becoming a Global Health Press subscriber. Join for exclusive articles, expert research, and valuable insights!
